CZ2005136A3 - Oprava mutagenního poskození DNA - Google Patents
Oprava mutagenního poskození DNA Download PDFInfo
- Publication number
- CZ2005136A3 CZ2005136A3 CZ20050136A CZ2005136A CZ2005136A3 CZ 2005136 A3 CZ2005136 A3 CZ 2005136A3 CZ 20050136 A CZ20050136 A CZ 20050136A CZ 2005136 A CZ2005136 A CZ 2005136A CZ 2005136 A3 CZ2005136 A3 CZ 2005136A3
- Authority
- CZ
- Czechia
- Prior art keywords
- aryl
- alkyl
- composition
- skin
- hydrogen
- Prior art date
Links
- 231100000219 mutagenic Toxicity 0.000 title claims abstract description 17
- 230000003505 mutagenic effect Effects 0.000 title claims abstract description 17
- 230000008439 repair process Effects 0.000 title claims description 11
- 230000006378 damage Effects 0.000 title claims description 7
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims abstract description 57
- 235000019126 equol Nutrition 0.000 claims abstract description 57
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims abstract description 57
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000005778 DNA damage Effects 0.000 claims abstract description 17
- 231100000277 DNA damage Toxicity 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 9
- 201000000849 skin cancer Diseases 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 25
- 230000005855 radiation Effects 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 19
- 102000003792 Metallothionein Human genes 0.000 claims description 19
- 108090000157 Metallothionein Proteins 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 17
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 239000000516 sunscreening agent Substances 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- -1 amino, thio Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 230000004224 protection Effects 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- CNNBJLXLTIKXGJ-UHFFFAOYSA-N 3-phenyl-2h-chromene Chemical compound C1OC2=CC=CC=C2C=C1C1=CC=CC=C1 CNNBJLXLTIKXGJ-UHFFFAOYSA-N 0.000 abstract description 9
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical class C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 78
- 210000003491 skin Anatomy 0.000 description 51
- 210000002615 epidermis Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 238000000254 composite pulse decoupling sequence Methods 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 239000008297 liquid dosage form Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000013635 pyrimidine dimer Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000025600 response to UV Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical class [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002951271A AU2002951271A0 (en) | 2002-09-06 | 2002-09-06 | Repair of dna mutagenic damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ2005136A3 true CZ2005136A3 (cs) | 2006-04-12 |
Family
ID=27671591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20050136A CZ2005136A3 (cs) | 2002-09-06 | 2003-09-05 | Oprava mutagenního poskození DNA |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060153781A1 (https=) |
| EP (1) | EP1534232A4 (https=) |
| JP (1) | JP2006501252A (https=) |
| CN (1) | CN1688285A (https=) |
| AU (1) | AU2002951271A0 (https=) |
| CA (1) | CA2497823A1 (https=) |
| CZ (1) | CZ2005136A3 (https=) |
| MX (1) | MXPA05002519A (https=) |
| NO (1) | NO20051605D0 (https=) |
| TR (1) | TR200500749T2 (https=) |
| WO (1) | WO2004022023A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104643057A (zh) | 2002-07-24 | 2015-05-27 | 儿童医院医疗中心 | 含有对映体牛尿酚的组合物和产物及其用途 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| WO2004039327A2 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| EP1542654A4 (en) * | 2002-09-23 | 2008-12-17 | Novogen Res Pty Ltd | TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2738510A1 (en) * | 2008-07-30 | 2010-02-04 | Novogen Research Pty Ltd | 6-substituted isoflavonoid compounds and uses thereof |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| CN114831981A (zh) * | 2021-02-02 | 2022-08-02 | 上海交通大学 | 一种ERβ选择性激动剂在抗肿瘤中的应用 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| AUPP868599A0 (en) * | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
| DE10121375B4 (de) * | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| DE10122342A1 (de) * | 2001-05-09 | 2002-11-14 | Beiersdorf Ag | Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen |
-
2002
- 2002-09-06 AU AU2002951271A patent/AU2002951271A0/en not_active Abandoned
-
2003
- 2003-09-05 EP EP03793484A patent/EP1534232A4/en not_active Withdrawn
- 2003-09-05 JP JP2004533066A patent/JP2006501252A/ja active Pending
- 2003-09-05 CN CNA038240114A patent/CN1688285A/zh active Pending
- 2003-09-05 CA CA002497823A patent/CA2497823A1/en not_active Abandoned
- 2003-09-05 TR TR2005/00749T patent/TR200500749T2/xx unknown
- 2003-09-05 US US10/526,830 patent/US20060153781A1/en not_active Abandoned
- 2003-09-05 CZ CZ20050136A patent/CZ2005136A3/cs unknown
- 2003-09-05 MX MXPA05002519A patent/MXPA05002519A/es active IP Right Grant
- 2003-09-05 WO PCT/AU2003/001152 patent/WO2004022023A1/en not_active Ceased
-
2005
- 2005-03-30 NO NO20051605A patent/NO20051605D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20051605L (no) | 2005-03-30 |
| NO20051605D0 (no) | 2005-03-30 |
| TR200500749T2 (tr) | 2005-10-21 |
| EP1534232A4 (en) | 2008-12-24 |
| AU2002951271A0 (en) | 2002-09-19 |
| EP1534232A1 (en) | 2005-06-01 |
| CN1688285A (zh) | 2005-10-26 |
| JP2006501252A (ja) | 2006-01-12 |
| CA2497823A1 (en) | 2004-03-18 |
| WO2004022023A1 (en) | 2004-03-18 |
| US20060153781A1 (en) | 2006-07-13 |
| MXPA05002519A (es) | 2005-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ2005136A3 (cs) | Oprava mutagenního poskození DNA | |
| JP2013523793A (ja) | パーソナルケア組成物 | |
| JPH10101543A (ja) | チロシナーゼ活性阻害剤及び化粧料 | |
| JP3340935B2 (ja) | メラニン生成抑制剤及び美白化粧料 | |
| JP2009155235A (ja) | フラボノイド類縁体又は生理的に許容されるその塩からなるメラニン産生抑制剤及び美白皮膚外用剤 | |
| JP2023025004A (ja) | 色素沈着過剰障害の処置方法 | |
| JP5139694B2 (ja) | メラニン産生抑制剤及び皮膚外用剤 | |
| CZ2005181A3 (cs) | Léčba stárnutí pokožky vlivem světla a aktinického poškození pokožky | |
| KR20220161172A (ko) | 세노모르픽스용 또는 피부 노화 방지용 조성물 | |
| AU2003257264B2 (en) | Repair of DNA mutagenic damage | |
| JP2010138153A (ja) | 紫外線予防用の皮膚外用剤 | |
| EP3003255B1 (en) | A photoprotective personal care composition | |
| JP2013209299A (ja) | Ｄｎａ損傷抑制剤並びにこれを含有する皮膚外用剤、化粧料および飲食物 | |
| JP2009155236A (ja) | マメ科ハギ属由来新規化合物を含有するメラニン産生抑制剤及び美白皮膚外用剤 | |
| JPH05509291A (ja) | フェニルアミン系脱色素、抗黒色腫剤 | |
| JP5768113B2 (ja) | 前処置用の皮膚外用剤の製造方法 | |
| JP2006232807A (ja) | 西洋わさび抽出物を含む抗酸化剤 | |
| KR100769579B1 (ko) | 피부 주름 개선용 화장료 조성물 | |
| JP4498593B2 (ja) | 育毛剤組成物 | |
| KR102224110B1 (ko) | Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물 | |
| RU2352322C1 (ru) | Дерматологическое и/или косметологическое средство, защищающее кожу от последствий воздействия повреждающих факторов, средство, обладающее способностью элиминировать клетки с выраженной хромосомной нестабильностью | |
| KR101386623B1 (ko) | 트리메틸파이토스핑고신을 포함하는 피부 미백용 조성물 | |
| JP2002087939A (ja) | リナカンツスナスツス抽出物及びその製造方法並びに育毛剤組成物 | |
| CN103747788A (zh) | 用喹硫平或其类似物治疗暴露于uv辐射的皮肤 | |
| JPH11124311A (ja) | 光毒性抑制剤 |